AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03278236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRF
Description: Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
Study NCT02406963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Photograph
Description: A digital photograph sent by the family of the surgical site
Study NCT02406963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Call
Description: Standard telephone call with the nurse practitioner
Study NCT02406963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Call
Description: Standard telephone call with the nurse practitioner
Study NCT03327285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR011
Description: CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)
Study NCT00293852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient clinic follow-up
Study NCT04410471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CLIA of IgG and IgM against SARS-Cov-2
Description: Report of clinical data
Study NCT00257738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3
Description: Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
Study NCT00257738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16 vaccine
Description: Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
Study NCT02775292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT02775292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02775292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02775292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02775292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02775292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL
Description: Given IV
Study NCT02775292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine
Description: Given ID
Study NCT02775292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Correlative studies
Study NCT03456687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
Study NCT01488747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coromega Omega-3 Squeeze
Description: 660 mg EPA, 434 mg DHA
Study NCT01488747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coromega Nectar
Description: 660 mg EPA, 436 mg DHA
Study NCT01488747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barleans Swirl
Description: 660 mg EPA, 660 mg DHA
Study NCT01488747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Omega-3 Softgel
Description: 660 mg EPA, 440 mg DHA
Study NCT02943187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
Study NCT02943187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Participants will be given dietary recommendations and nutritional supplements to optimize cognition.
Study NCT01033630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D&G 2g
Description: Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
Study NCT01033630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D&G 1g
Description: Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
Study NCT01033630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Image-matched placebo, made with starch.
Study NCT01460602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTD of Velcade, Nipent and Rituxan established in Part 1
Description: One of the following dose levels will be chosen and used in Part 2:~1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
Study NCT03730376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cost Information
Description: participants will be given information on the personal and societal costs
Study NCT00217581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Must be administered 1st before Docetaxel \& Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
Study NCT00217581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
Study NCT00217581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
Study NCT04420169 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A digital questionnaire to evaluate the communication by midwives will be send out to IVF patients
Study NCT01343537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuro Monitoring
Description: Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
Study NCT04441632 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive feedback
Description: Participants will submit positive feedback comments to their colleagues (anonymously or signed, participant-dependent) through an anonymous survey link, a minimum of twice weekly to 6 uniquely different individuals over a 4 week period (total minimum 24 unique individuals over the study period).
Study NCT02020135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA ADC
Description: Upon recommendation from the PI and after Sponsor approval, a subject benefiting from treatment could have received up to eight additional doses Q3W. Subjects were weighed prior to each cycle and dosing was calculated on a mg/kg basis prior to each dose, with a maximum weight of 100 kg for dosing calculations.
Study NCT01909973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedLink System
Description: Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status.
Study NCT01963507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
Study NCT04091737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
Description: * Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 in a bag for infusion~* Plerixafor to mobilize hematopoietic stem cells prior to each apheresis~* Single dose melphalan before administration of CSL200
Study NCT04452552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: healthy diet
Description: balanced diet program which ranged from 1600 kcal to 2000 kcal/day, which was calculated in an individual basis for each woman according to her basal metabolic rate (BMR) for 8 weeks
Study NCT01540981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIST Therapy
Description: FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.
Study NCT01540981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care consists of pressure relief, wound cleansing and dressing as needed
Study NCT05285787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPN-701 (Oral)
Description: MK-7
Study NCT00934245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Trivalent Influenza Vaccine
Description: Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
Study NCT00934245 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated polio vaccine (IPV)
Description: Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
Study NCT02363712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APOS shoe
Description: It consists of two shoes each with two large convex rubber balls called Pertupods screwed into the plantar surface of the sole so that a person walks on these balls.
Study NCT02363712 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-APOS shoe
Description: It has the same appearance as the APOS shoe, but without the rubber ball attachment on the plantar surface.
Study NCT00760487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof Toric IOL
Description: Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
Study NCT04425681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Treatment of LM With osimertinb
Study NCT04425681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment of LM With Bevacizumab
Study NCT02608242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH22189
Study NCT02608242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twynsta 80/10mg
Study NCT02608242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 20mg
Study NCT04121455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration
Study NCT03876470 — intervention group
Intervention type: OTHER
Intervention: Hepatitis C treatment as chosen by provider
Description: Participants' providers will determine the type of HCV treatment as appropriate.
Study NCT02748551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic procedures
Description: Laparoscopic surgery
Study NCT02748551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Surgery
Description: Open surgery
Study NCT04030429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 MG
Description: bid orally
Study NCT01594970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01%
Description: 1 drop in the affected eye(s), administered in the evening for 12 weeks.
Study NCT01367470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3 probiotic preparation
Description: VSL#3 is a mixture of 8 different strains of lactic acid bacteria and bifidobacteria at a concentration of 900 billion bacteria per sachet. The suggested dosage is 1 to 2 sachets per day.
Study NCT01367470 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo VSL#3
Description: Placebo VSL#3 is a base of corn starch containing no active ingredient.
Study NCT05101382 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Retrospective Observation of standard clinical practice
Study NCT01745575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 2mg tablets
Description: Reference product
Study NCT04121455 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
Study NCT04121455 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
Study NCT04121455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab every 2 weeks i.v. infusion
Study NCT01745575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg tablets
Description: Test product
Study NCT04121455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab every 3 weeks i.v. for 26 weeks
Study NCT04121455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: oral treatment according to current SPC
Study NCT03602196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal ultrasound assessment
Description: women were assessed in lithotomy position with an empty bladder at rest, perineal contraction and Valsalva maneuver using a linear translabial probe. We measure the distance between symphysis and ano-rectal angle. In the same position we investigate the levator ani viscoelastic properties using shear wave elastography at rest, Valsalva maneuver and maximal contraction. During the same examination, we assess the viscoelastic properties of the external anal sphincter using shear wave elastography for the 3 conditions: rest, Valsalva, contraction.~This pelvic floor muscles assessment is performed for each of the three planned visits~For the ancillary study on non pregnant women: viscoelastic properties of levator ani are assessed at rest, stretch and contraction using shear wave elastography.~This pelvic floor muscle assessment is performed for each of the two planned visit in the ancillary study.
Study NCT03602196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral muscles assessment
Description: The visco elastic properties of the biceps brachii muscle and the gastrocnemius medialis muscle are assessed rest, stretch and maximal contraction using shear wave elastography.~This peripheral muscle assessment is perform for each of the three planned visits.~For the ancillary study on non pregnant women: viscoelastic properties of biceps brachii and gastrocnemius medialis muscles are assessed at rest, stretch and contraction using shear wave elastography.~This peripheral muscles ultrasound assessment is performed for each of the two planned visit in the ancillary study.
Study NCT03602196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pelvic floor assessment
Description: Women undergo a pelvic floor assessment using the Pelvic organ prolapse quantification system. Such an assessment is performed for each of the three planned visits.~Women included in the ancillary study are not involved with this examination
Study NCT01977768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V7
Description: One pill of V7 once daily for 30 days together with standard of care TB drugs
Study NCT01977768 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04293484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal bilateral motor cortex and cathodal spinal tDCS
Description: 10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
Study NCT04293484 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Anodal bilateral motor cortex and cathodal spinal tDCS
Description: 10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
Study NCT02902770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)
Study NCT02902770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: IV ketorolac 30mg push
Study NCT02902770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Drip
Description: Normal Saline Drip Placebo given over 10 minutes
Study NCT02902770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Push
Description: Normal Saline Push Placebo
Study NCT04513067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YQ23
Description: YQ23 as a single agent will be given in Stage 1.
Study NCT04513067 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given in combination with YQ23 in Stage 2
Study NCT03949400 — intervention group
Intervention type: OTHER
Intervention: Exercise therapy and education.
Description: Exercise therapy and education, physiotherapy rehab at Aalborg Municipality
Study NCT04532567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205
Description: GLPG1205 film-coated tablets
Study NCT04532567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo film-coated tablets
Study NCT03771105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphate
Description: The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.
Study NCT03771105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phosphate
Description: The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.
Study NCT03168542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Fitting Guides
Description: Subjects who are habitual soft spherical or toric contact lens wearers, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guide, with either the Multifocal Contact Lens or an Investigational Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes during a 1 day visit.
Study NCT01686737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: * 12 weeks of Iyengar yoga~* 2 weekly sessions of 60 minutes
Study NCT01686737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: * 12 weeks of walking~* 2 weekly sessions of 60 minutes
Study NCT00543023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide 20 micrograms/day subcutaneous
Study NCT04293484 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham bilateral motor cortex and sham spinal tDCS
Description: 10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
Study NCT00543023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmon calcitonin 100 IU/day subcutaneous
Study NCT01782690 — intervention group
Intervention type: DRUG
Intervention: erlotinib
Description: Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
Study NCT01782690 — intervention group
Intervention type: DRUG
Intervention: gemcitabine
Description: Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
Study NCT02086305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional Care Model
Description: Symptom assessment and management, care goal setting, post-discharge support